J B Chemicals & Pharmaceuticals Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/a12u5jsuywz5q0rtqvb61vrf.pdf

Key Takeaways


Domestic Business: Chronic Strength, Acute Recovery

Chopra: "In the past 3 years, we have managed to transition the India domestic business from operating in stable, less growth segments to now operating majorly in progressive segments."

International Business: A Tale of Two Strategies


Ophthalmology Entry: Scale with Unanswered Margin Questions


CDMO: Capacity Built, Growth Levers Identified


Margins: Current Comfort, Future Upside

Khanna: "If there is no uncertainty and volatility, we should be maintaining the margins, which we currently have, right? Because we do not necessarily have to invest significantly in part of our existing domestic business."

Azmarda: Defending in a Tougher Market

Khanna: "Yes, we have some higher expectations in terms of volumes increase and the price is -- the competition is much more intensified because of some of the generic entry, but that is not cause of panic because we continue to protect our market share."

Guidance & Commitments

CommitmentSpecificsTimeline
South Africa rationalizationPortfolio pruning to continueThrough Q1 FY25
EBITDA margin25–27% (excluding ESOP)Current / ongoing
Domestic revenue growth200–300 bps above IPM (~12–13%)Ongoing
International formulations growthClose to 10%Ongoing
U.S. business scaleFrom $30 mn to $50 mnTwo to three years
CDMO business scaleClose to $50 mn near term; $100 mn longer termThree to five years
U.S. filings run rate3–4 ANDA filings per yearOngoing
Revenue mix ambitionIndia 60%, CDMO 20% (combined ~80%)Over time
Top-line growth (next year)12–14%FY25
EBITDA growth (next year)16–18%FY25
Ophthalmology portfolio detailsFull briefing on economics and strategyPost Q4 FY24 results
Margin guidance revisionUpward revision when chronic and CDMO contributions become substantialUndated

Key Metrics

MetricQ3 FY24
Revenue₹845 cr, up 7% YoY
Revenue growth excluding South Africa10% in Q3 FY24, 14% in 9M FY24
Domestic revenue₹462 cr, up 14% YoY
International revenue₹383 cr
Gross margin improvement530 bps YoY
Operating EBITDA margin27.8%
9M FY24 revenue₹2,622 cr, up 10% YoY
9M FY24 domestic revenue₹1,432 cr, up 14% YoY
9M FY24 international formulation revenue₹802 cr, up 6% YoY
9M FY24 operating EBITDA (ex-ESOP)₹729 cr, margin at 27.8%
IPM growth vs J.B. growth (IQVIA MAT Dec 2023)J.B. growing at 16% vs 10% IPM growth, fastest in top 25
Covered market (CVM) growth12%, J.B. domestic business within CVM growing at 16%
Sporlac franchise portfolio size (IQVIA MAT Dec 2023)₹121 cr
CDMO quarterly average revenue~₹100 cr per quarter
CDMO guidance$50 mn to $100 mn in 3 to 5 years
South Africa business size$30 mn this year, private:public mix now 60:40
U.S. business size~$30 mn, 15 owned ANDAs, filing 4-5 per year
Ophthalmology portfolio size (IMS reported)₹200 cr business
Net cash balance₹136 cr net positive
9M FY24 operating cash flow₹614 cr, 84% of YTD operating EBITDA
FY25 revenue growth guidance12% to 14%
FY25 EBITDA growth guidance16% to 18%
FY25 ESOP expense guidance₹45 cr to ₹48 cr full year
Domestic business growth target vs IPM200 to 300 bps above IPM growth
International formulation growth targetclose to 10%